Navitoclax (senolytic, ABT-263)

senolytic

In clinical trials in 6 of 9 markets tracked.

Evidence so far is from laboratory and animal studies.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (3)

T3 Faakye 2024 Preventing spontaneous cerebral microhemorrhages in aging mice: a novel approach targeting cellular senescence with ABT263/navitoclax doi:10.1007/s11357-023-01024-9
T3 Sierra-Ramirez 2020 Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin doi:10.18632/aging.103607
T1 Yang 2020 Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis doi:10.18632/aging.103177